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Abstract
Background: Although the inclusion of the HPV vaccine has been registered in Spain since 2007, vaccination rates are
lower than expected. The patients wish to be vaccinated is heavily influenced by information they have received from
many source. The Knowledge of primary health care professionals affects the information provided to patients and is
fundamental in the decision making. The aim of this study is to assess the opinions of primary health care professionals
on the vaccine against HPV and their knowledge about HPV infection and its links to with gynecological and
oropharyngeal cancer.
Methods: Cross-sectional study. A 19-item survey was drawn up. It included questions on basic aspects of HPV
infection and marketed vaccines, personal opinion about the inclusion in the immunization schedules and their level of
prescription and recommendation to patients in their clinical practice. From October 2013 to December 2013, 607
surveys were distributed among 20 primary health centers affiliated to the University Hospital 12 de Octubre. The
results were analyzed using SPSS statistical package.
Results: One hundred sixty four successfully completed surveys were obtained for analysis. 89 % of the professionals
knew about the relationship between HPV infection and cervical cancer, 57.3 % did not know any of the serotypes
against which vaccines are targeted; 40.4 % believed that there is insufficient data to support the commercialization of
the vaccines. Of these, 65.7 % argue that there is no data of its long-term effectiveness, 13.4 % that there is no data as
to its side effects, 13.4 % believed that the cost effectiveness is not worthwhile.
Conclusions: There is a strong controversy among health professionals regarding the marketing and inclusion of HPV
vaccine in immunization schedules. However, the knowledge of the primary care health professionals on key aspects of
infection and vaccine protection are insufficient. The training of professionals in vaccination, cervical pathology and
HPV infection should be improved to provide objective information on the use as this vaccine for patients.
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Background
Human papilloma virus (HPV) infection is the most
common sexual transmitted disease worldwide. The
overall prevalence of the infection in Spain is 14.3 %
(95 % Confidence interval (CI): 13.1 to 15.5), 28.8 %
(95 % CI: 26.6 to 31, 1) in women between 18 and
25 [1]. HPV infection is considered the most import-
ant risk factor for developing cervical cancer [2]. The
most frequently isolated genotypes in both malignant
and premalignant disease are HPV 16 and 18,
followed by 45 and 31 [3, 4].
Since 2006, two prophylactic HPV vaccines have been
available in Spain: Gardasil® (Merck & Co., Whitehouse
Station, NJ USA) and Cervarix® (GlaxoSmithKline Bio-
logicals, Rixensart, Belgium). They consist of the native
virus-like particles (VLPs), which are morphologically
and immunogenetically similar to virions, but lack in-
fectivity, replicative and tumorigenicity.
Both vaccines have demonstrated a high level of
effectiveness against genotypes 16 and 18 [5, 6].
Cervarix® contains VLPs genotypes 16 and 18. It has
been proved to be safe to administer in women up to
55 and has proved to generate protection for non-
vaccine genotypes 31 and 45 [7]. Gardasil® contains
VLPs genotypes 6, 11, 16 and 18. It has been also
proven to be safe to administer in women up to 45
and in males.
United States, Australia, Canada and the UK were the
first countries to introduce HPV vaccination into their
routine immunization programs. In February 2007 Spain
agreed to include the vaccine in the immunization
schedules for girls between 11–14. Furthermore, it was
agreed to recommend vaccination for all women up to
age 26 and individualized assessment of vaccination in
women over 26 years old and in males 9–26 years old
out of public funding.
However, rates of vaccination in Spanish women
have been lower than expected [8]. The controversy
of the benefits of vaccination and its relation to pos-
sible adverse reactions, and the existence of groups of
health care professionals with contrary opinions to
the vaccine implementation, could play an important
role in the low consumption of the vaccine. The more
information we give to the patients, the higher the
acceptance of the vaccine will be [9, 10]. The primary
health care professionals (PHCP) are the first stage to
transmiting information and opinion to patients.
The main objective of this study is to asses the
opinions of PHCP of primary care centers affiliated to
the Hospital 12 de Octubre (Madrid) on the vaccine
against HPV and their knowledge about its character-
istics and indications, and the basics concepts of HPV
infection and its links to with gynecological and oro-
pharyngeal cancers.
Material and methods
Cross-sectional study. The research was conducted in 20
primary health centers attached to the Hospital 12 de
Octubre.
To obtain the data, we drew up a survey consisting of
nineteen questions, 5 of open question format and 14 of
multiple choice questions. The survey is divided in four
sections (Fig. 1):
 Section I: Socio-demographic data, such as sex, age
and occupation.
 Section II: Knowledge of basics concepts of HPV
infection and vaccines marketed
 Section III: Personal opinion about the vaccine and
its inclusion in the immunization schedules.
 Section IV: Prescribing and recommending the
vaccine.
To design the survey, a literature review in databases
the PubMed-Medline and UPTODATE was carried out.
The keywords used were: Human papillomavirus, Vac-
cination, Cervical cancer.
The survey was aimed at PCHPs. Primary care physi-
cians; primary care pediatricians and primary care nurses
have been considered as PCHPs. Gynecologists have
been excluded from the study because they are not the
first stage to transmitting information and opinion on
the primary prevention strategies to patients in our pub-
lic health system.
The collected variables were included in an Excel data-
base. Statistical analysis was performed with SPSS, version
15.0. Incomplete Surveys were not taken into account. We
used the chi-square test to assess the significance of the
association between two categorical variables. Statistical
significance was considered as p < 0.05.
Results
From October 2013 to December 2013, 607 surveys
were delivered to 20 primary health centers attached to
the Hospital 12 de Octubre; Of them, 171 were com-
pleted and 164 of these were valid for the analysis. The
participation rate is 28 %. The percentage of men among
those who replied was 25 and 65.2 % of women. The
average age of participants was 46.6 years (SD ± 9.2,
range 23–64) (Table 1).
Section II: Knowledge of basics concepts of HPV infection
and vaccines marketed
A total of 101 (61.6 %) of participants didn´t know any
of the genotypes against which the bivalent vaccine
(HPV 16 and 18) protects. The 60.4 % (99) of partici-
pants didn´t know any of the genotypes against which
the quadrivalent vaccine protects (HPV 16,18,11,6). If
we combine the above data, we find that 57.3 % (94) of
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Fig. 1 Survey
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those who replied didn´t know any of the genotypes
against which both vaccines protect (Table 2).
Regarding the association between HPV infection and
the development of cancer, 89 % (146) of those who
replied knew the relationship between HPV and cervical
cancer. However, as reflected in Table 3, between 68 and
the 80 % of those who replied didn´t know that the rela-
tionship between HPV and the other carcinomas in
which it´s involved.
Regarding the indications of the vaccine, 7.9 % (13)
answered that the highest priority age range of the vac-
cine is 9–14. A total of 20 (12.2 %) didn´t answer this
question, and 80 % (130) of those who answered have
done so incorrectly.
Referring to the effectiveness of the vaccine (question
11), 65.45 % (104) knew that the vaccine has proven to
increase the amount of circulating antibodies and a
decrease in the incidence of high-grade cervical lesions.
However 17.6 % (28) wrongly answered that the vaccine
has been demonstrated to decrease the incidence of Ca.
Cervix.
Most of those who answered (45.1 %) reported having
obtained the information in medical journals, followed
by training seminars (38.41 %) and by pharmaceutical
representatives (32.9 %).
Section III: Personal opinion about the vaccine and its
inclusion in the immunization schedules
The 71.3 % (114) of participants consider that there is
no consensus of opinion on the inclusion of the vaccine
in the calendar among health professionals. Of these,
50 % (54) considered that a majority agrees with its
inclusion, 28.7 % (31) considered a balance between the
two positions and 21.3 % (23) considered that a majority
disagrees with its inclusion.
The 40.4 % (65) of those who answered think that there
is insufficient data to support the commercialization of
the vaccine. The most frequent reason given (65.7 %) is
that they think there is no data on long-term effectiveness.
The 59.6 % (96) of the professionals vary on their
opinion on the use of the vaccine in the public health
system. The 32.3 % of those who answered think that
the coverage of the age range is insufficient.
Section IV: Prescribing and recommending the vaccine
According to the personal experience of the profes-
sionals, 75.8 % (124) of them, consider <25 % the per-
centage of women between 15 and 50 years old that ask
for information about the vaccine, 17.6 % (28) consider
this percentage to be around 25-50 %, 2.6 % (5) around
50-75 % and 3.9 % (7) in ≥75 %.
The 77.5 % (124) of participants thinks that the num-
ber of patients who agree to be vaccinated would be
higher if it were cheaper. However, 82.4 % (131) did not
change their own opinion despite decrease in price.
The 72 % (108) of participants recommended the vac-
cine only to women and 27.3 % (41) to both sexes;
59.8 % (98) recommended the vaccine to the age range
of 14–26, 57.3 % (94) to the age range of 11–14 years,
and 15.2 % (25) to the over 26. 58.2 % (92) of partici-
pants recommended vaccination of their own family
members aged between 11 and 26.
When we analyzed the degree of recommendation of
the vaccine based on proven knowledge about it (ques-
tion 11) we notice that those professionals who cor-
rectly answered the question 11, recommend further
vaccination (72.9 vs. 45 %; p-value 0.6). The belief that
the vaccine has been shown to decrease the incidence
of cervical cancer also implies an increase in the per-
centage of professionals who recommend the vaccine
(23.4 vs. 9.7 %).
Table 1 Socio-Demographic Data (N = 164)
Women 107 (65.2)
Men 57 (34.8)
Mean age (years) 46.6 ± 9.2 (23–64)
Proffesion :
• PHCPs 97 (59.1)
• Nurse 51 (31.2)
• Pediatrician 16 (9.7)
Mean of years of professional experience (years) 18.8 ± 9.2 (1–39)
Value in n(%) or Mean ± ST (Range)
Table 2 Knowledge of genotypes included in the vaccine (N= 164)
Bivalent vaccine (Cervarix ® contains VLPs of HPV 16 and 18)
• Knowledge of HPV 16 1 (0.61)
• Knowledge of HPV 16 and 18 62 (37.8)
• No knowledge of any of them 101 (61.6)
Quadrivalent vaccine (Gardasil® contains VLPs OF HPV 16, 18, 11 y 6)
• Knowledge of all of them 54 (32.9)
• No knowledge of any them 99(60.4)
• Knowledge of HPV 16 and 18 5 (3)
• Knowledge of HPV 11 and 18 1 (0.6)
• Knowledge of HPV 6 and 18 1 (0.6)
• Knowledge of HPV 6, 11 and 18 2 (1.22)
• Knowledge of HPV 11, 16 and 18 2 (1.22)
Global knowledge
• Knowledge of every genotypes of both vaccine 46 (28)
• Knowledge of the genotypes of bivalent vaccine. 16 (9.7)
• Knowledge of the genotypes of quadrivalent vaccine. 8 (4.8)
• No knowledge of any of the serotypes 94 (57.3)
Value in n (%) or Mean ± ST (Range))
Pérez et al. Infectious Agents and Cancer  (2015) 10:41 Page 3 of 6
The recommendation of the vaccine is also influenced
by the factors that could be used in marketing the pro-
fessionals have considered to be the most influential.
Those who think that the effectiveness and risk data are
the most important factors, recommend the vaccine
more (77.4 vs. 18.5 %), while those who think that the
commercial interests of pharmaceutical industry is the
most important factor, recommended the vaccine to a
lesser degree (11.8 vs. 56.9 %).
Professionals who have obtained information from con-
ference attendance recommend to a greater extent the
routine vaccination against those who have not attended
courses and conferences (76.8 vs. 53.4 %; p-value = 0.008).
Likewise, those who have received the information from
training seminars also recommend the routine vaccination
more often (73 vs. 51 %; p-value 0.006).
Discussion
The clinical trials published have demonstrated an ef-
fectiveness of nearly 100 % of both vaccines in women
between 15 and 26 years old. Also, high immunogenicity
in children under 15 years old has been demonstrated
[11, 12]. This has conditioned the modification of vac-
cination schedules in many countries.
Although the risk of HPV infection is higher at the
beginning of sexual activity, it remains high throughout
the sex life. Each year, 5-15 % of middle-aged women
acquire a new infection [13, 14]. On the other hand, the
older the patient, the higher the probability of persistent
infection and, therefore, increased risk of development
cervical cancer. Several studies have confirmed the ef-
fectiveness of the quadrivalent vaccine in women until
the age of 45 and the bivalent vaccine in women older
than 26 [15, 16].
In Spain, the systematic vaccination against HPV was
established in February 2007 for children between 11–14
years. Out of public funding, it was agreed to recom-
mend vaccination for all women younger than 26 years
and individualized assessment of vaccination to women
over 26 years and in males 9–26 years. However, rates of
vaccination in the population included in the public
funding are lower than expected [8].
The vaccination rates are directly associated with the
information provided to women on HPV infection and
the characteristics of the vaccines [9]. The PHCPs are
the first stage transmitting information and recommend-
ing the vaccine. The information given by professionals
to the patients is conditioned by their own knowledge of
the vaccines and their personal opinion on them.
In 2008, the Spanish scientific societies published a
consensus document, based on the available evidence of
the HPV vaccine, establishing the indications for the use
of the vaccine. Three years later, in 2011, the impact of
that document hadn´t been as successful as it was to
thought it should have been. Because of persistent
doubts about the usefulness of the recommendations on
vaccination against HPV, its effectiveness and risk [17] a
new consensus document focused on HPV vaccination
was published in 2011 [18].
In our study, we analyzed the knowledge of PCPs about
HPV infection and the basic characteristics of the vac-
cines. The 89.2 % of participants know the relationship
between HPV and cervical cancer. However, it highlights
their lack of Knowledge about genotypes included in the
vaccines (57.3 % didn´t know the serotypes against which
both vaccines protect), and the relationship of HPV with
cancer of the vagina, penis, vulva, oropharynx or anus
(79.88, 73.78, 71.95, 70.12 and 68.29 %).
One of the most important data obtained in our study
is that 40.4 % of participants think that there is insuffi-
cient data to support the commercialization of the vac-
cine. The main reason they consider (65.7 %) is there are
no long-term studies on the influence of vaccination on
mortality from cervical cancer. The 13.4 % state that
there are no studies of long-term risk of the vaccine,
cost effectiveness (10.4 %), the possible need for revac-
cination (4.5 %) and the replacement of ecological niche
for other HPV types (6 %).
Recently, Naud et al. have published their data of a long-
term study with 9.4 years of follow-up in women vaccinated
with Cervarix®. The effectiveness against CIN 2 was 100 %
and 100 % of women remained seropositive against sero-
types 16 and 18, with titers at least 10 times higher com-
pared with natural immunity [19]. In addition, there are
mathematical models that predict that the antibodies are to
remain high for at least 20 years or even a lifetime [20].
Approximately 120 million doses of vaccine have been
distributed worldwide. No serious adverse effects related
to the vaccine have been observed in none of the clinical
trials done [16, 18, 21]. The most frequently reported
adverse effects were transient and at the part of the body
where it was injected [22].
Table 3 Comparison of professionals who support the
vaccination vs. professionals who don´t support the vaccination
Support the vaccination




No 32 (45 %) 39 (54.9 %)
Yes 62 (72.9 %) 23 (27 %) 0.696
Information from
congress
No 63 (53.4 %) 55 (46.6 %)
Yes 33 (76.8 %) 10 (23.2 %) 0.008
Information from
training seminars
No 50 (51 %) 48 (49 %)




No 50(52.6 %) 45 (47.4 %)
Yes 46 (71,8 %) 18 (28.2 %) 0.015
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Regarding the cost effectiveness of the introduction
of the vaccine as part of routine vaccination, the World
Health Organization has established that HPV vaccin-
ation combined with a redesigned screening is the most
effective strategy for the prevention of cervical cancer
[23]. Castellsagué et al. studied the impact of the vac-
cine in Spain with a mathematical model simulation.
According to their conclusion with the combination of
systematic vaccination in children, the stimulation of
vaccination in young women outside public funding
and the current screening programs, 83.5 % of total
costs associated with these diseases (168 million euros
per year) would be reduced [24, 25].
On the other hand, note the perception of 75.8 % of par-
ticipants that less than 25 % of women between 15 and 50
ask for the vaccine. This may be due to of a lack of infor-
mation or knowledge within the general population about
the implications of HPV infection, its causal association
with cervical cancer and the importance of primary pre-
vention. One of the causes for low immunization coverage
in young adult women described in several epidemio-
logical studies is the lack of awareness about the disease
and concern about side effects of vaccination [26].
The main factor associated with the use of vaccine is
the information that women have about the mechanism
of HPV infection and its implication in several cancers
and the effects of vaccination in terms of effectiveness
and risk. It is important emphasize on the advantages of
the systematic vaccination and individualization of each
case in women over 14 [26].
The PHCPs are the first patient contact with the pro-
grams of primary and secondary prevention. The informa-
tion that these professionals provide to their patients
influences their decision-making. Therefore, such infor-
mation must be based on the available scientific evidence.
Our study shows that there is a knowledge gap in pri-
mary health care professionals on basic aspects of HPV
infection and its associated lesions, as well as the charac-
teristics of vaccines and the population susceptible to
receive it.
It is essential to ensure the training and continuous
updating of professionals to provide dissemination of
appropriate information to our patients and, conse-
quently, facilitate and improve national HPV vaccine
coverage.
Conclusions
The information given to patients about HPV, cancer and
vaccine are the most important factors on vaccination
(greater knowledge, greater acceptance). The knowledge
and training of primary care professionals in this area
should be enhanced, in order to improve the information
given to our patients.
Limitations of study
Our results cannot be extrapolated to all PHCPs in
Spain. Although the participation rate is acceptable and
similar to those obtained by other authors such as Torné
et al. [26] with a share of 40.4 %, or Mazzadi et al. [27]
with a share of 15.23 %, it still remain a low percentage.
It could be biased towards those professionals most
motivated in participate.
Abbreviations
HPV: Human papilloma virus; PCPs: Primary care professionals; STD: Sexual
transmitted disease; CI: Confidence interval; VLPs: Native virus-like particles;
GP: General practitioners; CIN: Cervical intraepithelial neoplasia; WHO: World
Health Organization.
Competing interests
The authors declare that they have no competing interests
Authors’ contributions
MRO: Conceived of the study, participated in its design and coordination,
performed the statistical analysis and drafted the manuscript; VVV:
Participated in the coordination of the study and helped to draft the
manuscript; AVC: Participated in the design of the study, recruit data and
helped to draft the manuscript; CR: Participated in the design of the study,
recruit data and helped to draft the manuscript; SYC: Participated in the
design of the study, recruit data and helped to draft the manuscript; LPC:
Participated in the design of the study, recruit data and helped to draft the
manuscript; JSJ: Participated in the coordination of the study and helped to
draft the manuscript. All authors read and approved the final manuscript.
Author details
1Department of Gynecologic Oncology, Hospital Universitario 12 de Octubre,
Avda Cordoba s/n, Madrid, Spain. 2Department of Obstetrics and
Gynecology, School of Medicine, Complutense University, Madrid, Spain.
Received: 23 June 2015 Accepted: 23 September 2015
References
1. Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, et al. San
Martin Rodriguez M, Serradell L, Torcel-Pagnon L, Cortes J;CLEOPATRE Spain
Study GroupCLEOPATRE Spain Study Group. Prevalence and genotype
distribution of human papillomavirus infection of the cervix in Spain: The
CLEOPATRE Study. J Med Virol. 2012;84(6):947–56.
2. Muñoz N, Castellsagué X, de Gonzalez AB, Gissman L. Champter 1: HPV in
the etiology of human cáncer. Vaccine. 2006;24 Suppl 3:S1–S10.
3. Alemany L, Pérez C, Tous S, Llombart-Bosch A, Lloveras B, Lerma E, et al.
Spanish study group RIS HPV TT. Human papillomavirus genotype
distribution in cervical cancer cases in Spain. Implications for prevention.
Gynecol Oncol. 2012;124:512–51.
4. Castellsagué X, Cohet C, Puig-Tintoré LM, Acebes LO, Salinas J, San Martin
M, et al. Epidemiology and cost of treatment of genital warts in Spain.
Eur J Public Health. 2009;19:106–10.
5. Castellsague X, Garland SM. A review of clinical trials of human
papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–38.
6. De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras
B, et al. Retrospective International Survey and HPV Time Trends Study
Group. Human papillomavirus genotype attribution in invasive cervical
cancer: a retrospective cross-sectional worldwide study. Lancet Oncol.
2010;11(11):1048–56.
7. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction
of immune memory following administrationof a prophylactic quadrivalent
human papillomavirus (HPV) types 6/11/16/18 L1 virus-likeparticle (VLP)
vaccine. Vaccine. 2007;25:4931–9.
8. Limia A, Pachón I. Coverage of human papillomavirus vaccination during the
first year of its introduction in Spain. Euro Surveill 2011;16(21):pii = 19873.
9. Black LL, Short MB, Sturm L, Rosenthal SL. Literature review of human
papillomavirus vaccine acceptability among women over 26 years. Vaccine.
2009;27:1668–73.
Pérez et al. Infectious Agents and Cancer  (2015) 10:41 Page 5 of 6
10. Wu JP, Porch E, McWeeney M, Ohman-Strickland P, Levine JP. Knowledge
and concerns related to the human papillomavirus vaccine among
underserved Latina women. J Low Genit Tract Dis. 2010;14:155–61.
11. Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernández-Ávila
M, et al. Four year efficacy of prophylactic human papillomavirus
quadrivalent vaccine against low grade cervical, vulvar, and vaginal
intraepithelial neoplasia and anogenital warts: randomised controlled trial.
BMJ. 2010;341:c3493.
12. Wheeler CM, Castellagué X, Garland SM, Szarewski A, Paavonen J, Naud P,
et al. Cross-protective efficacy of HPV-16/18 AS04- adjuvanted vaccine
against cervical infection and precancer caused by non-vaccine oncogenic
HPV types: 4-year end-of- study analysis of the randomised, double-blind
PATRICIA trial. Lancet Oncol. 2012;13:100–10.
13. Muñoz N, Méndez F, Posso H, Molano M, Van den Brule AJ, Ronderos M, et al.
Incidence, duration, and determinants of cervical human papillomavirus
infection in a cohort of Colombian women with normal cytological results.
J Infect Dis. 2004;190(12):2077–87.
14. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S,
et al. Incidence, clearance and predictors of human papillomavirus infection
in women. CMAJ. 2003;168(4):421–5.
15. Castellagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al.
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV
(types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of
age. Br J Cancer. 2011;105(1):28–37.
16. Muñoz N, Manalastas Jr R, Pitisuttithum P, Tresukosol D, Monsonego J,
Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human
papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged
24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–57.
17. Cortés J, Martinón-Torres F, Ramón y Cajal JM, Ferret G, Gil A.
Considerations on the clinical application of the human papillomavirus
vaccine in Spain. Hum Vaccines. 2011;7(5):585–9.
18. Cortés Bordoy J. Vaccination against the human papilloma virus. Consensus
statement 2011 of the scientific Spanish societies. Semergen.
2012;38(5):312–26.
19. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC,
Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the
HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up
study up to 9.4 years post-vaccination. Hum Vaccin Immunother.
2014;10(8):2147–62.
20. David M-P, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, et al.
Long-term persistence of antiHPV-16 and −18 antibodies induced by
vaccination with the AS04- adjuvanted cervical cancer vaccine: modelling of
sustained antibody responses. Gynecol Oncol. 2009;115(Supple3):S1–6.
21. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, et al. Surveillance
of autoimmune conditions following rou- tine use of quadrivalent human
papillomavirus vaccine. J Intern Med. 2012;271:193–203.
22. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human
papillomavirus (HPV) vaccines: a review of the international experience so
far. Vaccine. 2009;27:7270–81.
23. Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C. Screening, prevention and
treatment of cervical cancer-A global and regional generalized cost-effectiveness
analysis. Vaccine. 2009;27(43):6060–79.
24. Largerón N, Rémy V, Oyee J, San-Martín M, Cortés J, Olmos L. Análisis de
coste- efectividad de la vacunación frente al virus del papiloma humano
tipos 6, 11, 16 y 18 en España. Vacunas. 2008;9:3–11.
25. Castellsaué X, San Martín M, Cortés J, Gonzalez A, Remy V. Impacto de la
vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6,11,
16 y 18 en las enfermedades asociadas al VPH en España. Prog Obsttet
Ginecol. 2008;51:520–30.
26. Torné A, Bayas J, Castellsagué X, Castro M, García E, Martínez J. Vacunación
frente al cáncer de cérvix en mujeres fuera de los programas de vacunación
sistemática, con o sin infección por el virus del papiloma humano o lesión
cervical. Encuesta de opinión y recomendaciones. Prog Obstet Ginecol.
2012;55:10–31.
27. Mazzadi A, Palomino M, Arrossi S. Aceptabilidad y conocimientos sobre la
vacunación contra el virus del papiloma humano (VPH) en médicos
ginecólogos de Argentina. Salud Pública Mex. 2012;54:515–22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pérez et al. Infectious Agents and Cancer  (2015) 10:41 Page 6 of 6
